Free Trial

Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Price Target at $31.00

ARS Pharmaceuticals logo with Medical background

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have received an average rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $31.00.

A number of equities analysts have recently weighed in on SPRY shares. Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Scotiabank initiated coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective on the stock. Finally, William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd.

Check Out Our Latest Stock Report on ARS Pharmaceuticals

ARS Pharmaceuticals Trading Up 7.4%

Shares of SPRY traded up $1.09 during midday trading on Monday, hitting $15.91. The stock had a trading volume of 2,727,308 shares, compared to its average volume of 1,305,300. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The business has a 50-day simple moving average of $14.29 and a two-hundred day simple moving average of $12.86. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.56 billion, a P/E ratio of -99.43 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The business had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. As a group, equities analysts forecast that ARS Pharmaceuticals will post -0.55 EPS for the current year.

Insider Activity at ARS Pharmaceuticals

In related news, CFO Kathleen D. Scott sold 50,000 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $705,000.00. Following the transaction, the chief financial officer now owns 7,424 shares of the company's stock, valued at approximately $104,678.40. The trade was a 87.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Brent L. Saunders sold 120,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total value of $1,710,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 322,971 shares of company stock valued at $4,481,888. Corporate insiders own 33.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Alliancebernstein L.P. grew its holdings in shares of ARS Pharmaceuticals by 1.1% in the 1st quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company's stock worth $49,349,000 after purchasing an additional 42,071 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of ARS Pharmaceuticals by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 3,488,293 shares of the company's stock worth $43,883,000 after acquiring an additional 23,341 shares in the last quarter. Cormorant Asset Management LP increased its holdings in ARS Pharmaceuticals by 220.0% during the 1st quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock valued at $20,128,000 after purchasing an additional 1,100,000 shares in the last quarter. MPM Bioimpact LLC acquired a new stake in ARS Pharmaceuticals during the 1st quarter valued at $16,519,000. Finally, Alyeska Investment Group L.P. raised its position in ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock valued at $13,227,000 after purchasing an additional 1,128,724 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

(Get Free Report

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Recommended Stories

Analyst Recommendations for ARS Pharmaceuticals (NASDAQ:SPRY)

Should You Invest $1,000 in ARS Pharmaceuticals Right Now?

Before you consider ARS Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.

While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines